| Literature DB >> 24020893 |
Marlies Karsch-Völk1, Elisa Schmid, Stefan Wagenpfeil, Klaus Linde, Uwe Heemann, Antonius Schneider.
Abstract
BACKGROUND: In elderly patients chronic kidney disease often limits drug prescription. As several equations for quick assessment of kidney function by estimating glomerular filtration rate (eGFR) and several different clinical recommendations for drug dose adjustment in renal failure are published, choosing the correct approach for drug dosage is difficult for the practitioner. The aims of our study were to quantify the agreement between eGFR-equations grouped by creatinine-based or cystatin C-based and within the groups of creatinine and cystatin C-based equations and to investigate whether use of various literature and online references results in different recommendations for drug dose adjustment in renal disease in very elderly primary care patients.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24020893 PMCID: PMC3850264 DOI: 10.1186/1471-2318-13-92
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Physical and biochemical patient characteristics
| Female sex | 79 (73) |
| Age (years) | 85 (80–102) |
| Body Mass Index (kg/m2) | 26.0 (16.7-47.1) |
| Number of diagnoses | 9 (2–17) |
| Number of drugs/day | 7 (1–19) |
| Creatinine (mg/dl) | 1.0 (0.5-3.2) |
| Cystatin C (mg/l) | 1.2 (0.6-3.4) |
| eGFR Cockroft-Gault (ml/min/1,73 m2) | 45.3 (12.2-95.8) |
| eGFR MDRD (ml/min/1,73 m2) | 53.2 (14.8-118.1) |
| eGFR Grubb (ml/min/1,73 m2) | 63.5 (11.1-174.5) |
| eGFR Hoek (ml/min/1,73 m2) | 65.5 (19.7-123.2) |
| eGFR Perkins (ml/min/1,73 m2) | 87.0 (29.9-158.7) |
Most common diagnoses as documented in patient charts as coded in ICD 10
| Hypertension | 94 (87) |
| Arthrosis | 58 (54) |
| Cardiac failure | 54 (50) |
| Hyperlipidemia | 49 (45) |
| Type 2 diabetes mellitus | 43 (40) |
| Coronary heart disease | 35 (32) |
| Chronic kidney failure (no dialysis required) | 32 (30) |
| Hyperuricemia | 29 (27) |
| Atrial fibrillation | 28 (26) |
| Depression | 21 (19) |
| Incontinence | 21 (19) |
| Peripheral artery occlusive disease | 21 (19) |
| Struma | 19 (18) |
| Dementia | 13 (12) |
| Chronic obstructive pulmonal disease (COPD) | 12 (11) |
Most commonly taken remedies
| Angiotensin-converting enzyme inhibitor* | 59 (55) |
| Hydrochlorothiazide* | 59 (55) |
| Beta-adrenoceptor blocker** | 54 (50) |
| Acetylsalicylic acid* | 41 (38) |
| Non steroidal anti inflammatory drugs* | 23 (21) |
| Statins** | 22 (20) |
| Antidepressants** | 18 (17) |
| Opioids** | 18 (17) |
| Sartans** | 17 (16) |
| Allopurinol* | 10 ( 9) |
| Bisphosphonates* | 8 ( 7) |
| Neuroleptics** | 8 ( 7) |
| Sulfonylureas* | 8 ( 7) |
| Acetaminophen (Paracetamol)* | 7 (.7) |
| Metformin* | 7 ( 7) |
| Metoclopramide* | 7 ( 7) |
| Aldosterone antagonists* | 4 ( 4) |
| Antidementives** | 2 ( 2) |
| Antiepileptics** | 2 ( 2) |
| Alpha2 adrenergic receptor antagonists* | 2 ( 2) |
| Digoxin* | 2 ( 2) |
| H2 receptor antagonists* | 2 ( 2) |
| Disease modifying antirheumatic drugs** | 2 ( 2) |
* All drugs in this class require dose adjustment in case of moderate or severe renal impairment.
** Some drugs of this class require dose adjustment in case of renal impairment.
Intraclass-correlation coefficients for eGFR according to different equations
| MDRD | 0.87 (0.81-0.91) | 0.76 (0.66-0.83) | 0.65 (0.53-0.75) | 0.73 (0.63-0.81) |
| CG | | 0.69 (0.57-0.78) | 0.54 (0.39-0.66) | 0.63 (0.50-0.73) |
| Hoek | | | 0.90 (0.85-0.93) | 0.98 (0.97-0.98) |
| Grubb | 0.96 (0.95-0.98) |
CG = Cockroft-Gault; MDRD = Modification of Diet in Renal Disease;
95% CI = 95% confidence interval.
Figure 1Scatter plots illustrating the relation between the results of the two creatinine-based and the three cystatin C-based equations.Figure Legend: R2 Linear: linear regression coefficient. CG = Cockroft Gault; MDRD = Modification of Diet in Renal Disease.
Differences in the number of drugs that may require dose adjustment in kidney failure per patient according to the five literature sources
| 0 | 7 (6%) | 4 (13%) | 9 (8%) | 11 (10%) | 7 (7%) |
| 1 | 37 (34%) | 19 (18%) | 18 (17%) | 23 (21%) | 16 (15%) |
| 2 | 33 (31%) | 40 (37%) | 28 (26%) | 40 (37%) | 34 (32%) |
| 3 | 21 (19%) | 25 (23%) | 36 (33%) | 25 (23%) | 31(29%) |
| 4 | 9 (8%) | 7 (6%) | 13 (12%) | 7 (7%) | 12 (11%) |
| 5 | 1 (1%) | 3 (3%) | 3 (3%) | 1 (1%) | 5 (5%) |
| 6 | | | 1 (1%) | 0 (0%) | 3 (3%) |
| 7 | | | | 1 (1%) | |
| M (SD) | 1.92 (1.10) | 2.01 (1.20) | 2.36 (1.26) | 2.02 (1.20) | 2.48 (1.34) |
Friedman-test for comparison of all literature sources: p < 0.001; Wilcoxon-test paired samples: p < 0.001 for Renal Drug HB vs. AMP, Dosing vs. AMP, Renal Drug HB vs. DPRF, Dosing vs.DPRF, AMP vs. BNF, BNF vs. DPRF, and p = 0.39 for Renal Drug HB vs. Dosing, p = 0.36 for RDB vs. BNF, p = 0.95 for Dosing vs. BNF, p = 0.22 for AMP vs. DPRF;
M = Mean, SD = Standard deviation;
Renal Drug HB = The Renal Drug Handbook (19), Dosing = http://www.dosing.de (21), AMP = Arzneimittel Pocket (22), BNF = British National Formulary (20), DPRF = Drug Prescibing in Renal Failure (18).
Agreement beyond chance (Kappa coefficients) among different references regarding necessary drug changes when using the Cockroft-Gault equation for estimating eGFR
| Renal Drug HB | 0.15 | 0.10 | 0.23 | 0.20 |
| (0.00-0.32) | (0.00-0.34) | (0.06-0.40) | (0.03-0.36) | |
| Dosing | | 0.62 | 0.51 | 0.19 |
| (0.47-0.78) | (0.35-0.68) | (0.02-0.35) | ||
| AMP | | | 0.49 | 0.19 |
| (0.34-0.65) | (0.05-0.34) | |||
| BNF | | 0.57 | ||
| (0.40-0.73) |
95% CI = 95% confidence interval;
Renal Drug HB = The Renal Drug Handbook (19), Dosing = http://www.dosing.de (21), AMP = Arzneimittel Pocket (22), BNF = British National Formulary (20), DPRF = Drug Prescibing in Renal Failure (18).